The main objective of EBOVAC2 is to provide extensive and robust data on the safety and immunogenicity of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.

This will be done by:

  1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates;
  2. Carrying out Phase 2 trials in African and European volunteers. Given the compressed nature of this development program, the Phase 2 studies are anticipated to be conducted in parallel with the planned Phase 3 study (EBOVAC1). The EBOVAC2 Phase 2 studies will be controlled with either placebo or active control vaccinations with standard vaccines and will be conducted in locations where it is possible to perform carefully controlled safety studies;
  3. Evaluating the use of the vaccine regimen in healthy population groups, such as children (aged 1-17 years), the elderly (ages 50-65) and individuals infected with HIV, to confirm safety and immunogenicity. It is intended that Phase 2 trials will begin as soon as preliminary safety data are available from Phase 1 trials;
  4. Monitoring and characterising immune response to the proposed vaccine regimen;
  5. Boosting the capacity of African centres and staff as well as communicating and disseminating the results of EBOVAC2 as they become available to all key stakeholders;
  6. Contributing all data to the Central Information Repository (set up in EBOVAC1) for use by all Ebola+ projects as well as the wider community.

laboratory compressed                                                    © Janssen


  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings


Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as NotAllowedScriptReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions